From: Early detection of amyloid load using 18F-florbetaben PET
Dataset identifier | Source | Clinical diagnosis | Number | Age | M/F | Methods |
---|---|---|---|---|---|---|
#1 | NCT00928304† | yHC | 65 | 27.4 ± 5.1 | 25/40 | Sample of yHC (20–40 yrs) that underwent a 18F-florbetaben PET scan. This subset was used to develop an SUVR cutoff for early Aβ accumulation. |
#2 | NCT00750282 [13] | eHC AD | 66 73 | 68.0 ± 6.9 71.0 ± 7.9 | 28/38 41/32 | All subjects underwent a 18F-florbetaben PET scan. This subset was used to develop an SUVR cutoff for established Aβ pathology using ROC analysis. |
#3 | EudraCT: 2014-000798-38 [26] | SCD | 168 | 64.9 ± 7.3 | 65/103 | SCD patients from the Fundació ACE Healthy Brain Initiative (FACEHBI) study that underwent two 18F-florbetaben PET scans at baseline and after 2 years. This subset was used to assess the Aβ accumulation over time. |
#4 | NCT01138111 [18] | MCI | 44 | 72.6 ± 6.6 | 28/16 | MCI subjects that underwent three 18F-florbetaben PET scans at baseline (n = 44), 1 yr (n = 40), and 2 yrs (n = 35) and a 4-year clinical follow-up. This subset was used to assess the Aβ accumulation over time and conversion to AD. |
#5 | NCT02854033 (ADNI3‡) | eHC MCI AD | 157 85 28 | 70.6 ± 6.1 71.7 ± 8.1 71.3 ± 7.0 | 62/95 47/38 18/10 | Subjects from the ADNI3 study that underwent a 18F-florbetaben PET and a 18F-flortaucipir PET. This subset was used to assess the association between Aβ and tau deposition. |